You are here: Industry Insights > Amgen

News List

Amgen submits applications in the US and Europe to expand current indication for Xgeva cphi-online
April 06, 2017
Applications include data from the largest international trial conducted in multiple myeloma.
Lowering LDL Levels with Repatha(R) (evolocumab) Did Not Adversely Affect Cognitive Function in Land prnasia
March 21, 2017
Amgen announced detailed results from the Repatha® (evolocumab) cognitive function trial (EBBINGHAUS) evaluating the impact on cognitive function in 1,974 patients enrolled in the Repatha cardiovascular outcomes study (FOURIER).
Amgen accuses biosimilar producer of ‘massive conspiracy’ pharmafile
March 10, 2017
Amgen has filed a lawsuit in a Californian state court against Coherus Biosciences, suggesting that Coherus had stolen trade secrets. The case is in regards to the development of Coherus’ biosimilar to Amgen’s Neulasta.
Repatha receives EC approval for new 420 mg single-dose delivery option cphi-online
February 24, 2017
Approval of the automated mini-doser marks first hands-free administration option for a PCSK9 inhibitor in Europe.
Amgen vs. Sanofi – appeals court suspend patent injunction europeanpharmaceuticalreview
February 10, 2017
“Protecting intellectual property is essential to our industry as it reinforces the incentives for the large and risky investments we make in innovation to bring forward new medicines to treat serious diseases,” said Robert Bradway, chairman and CEO at Am
Amgen's Repatha significantly reduced the risk of cardiovascular events in FOURIER outcomes study cphi-online
February 08, 2017
Landmark Repatha cardiovascular outcomes study meets primary and key secondary endpoint.
Amgen, DaVita Enter New Sourcing And Supply Agreement - See more at: http://www.contractpharma.com/c January 10, 2017
Amgen will supply EPOGEN and Aranesp for dialysis services in the U.S. and Puerto Rico

Previous page 1 2 3 4 5 6 7 8 9 10 ... 22 23 Next page